Nathaniel A. Long

Nathaniel A. Long

Auto-generated profile, based on publicly available information

Nathaniel A. Long

Penn State College of Medicine, Hershey, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2022 in Stem Cell Reviews and Reports
Verified
Journal Article
Closed access
PDF file
NLNathaniel A. Long
Nathaniel A. Long
Upendar Rao GollaUpendar Rao Golla
Upendar Rao Golla
ASArati Sharma
Arati Sharma
DCDavid Claxton
David Claxton

5 September 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JLJie Li
Jie Li
PWPing-Yuan Wang
Ping-Yuan Wang
NLNathaniel A. Long
Nathaniel A. Long
JZJie Zhuang
Jie Zhuang
DSDanielle A. Springer
Danielle A. Springer
PHPaul M. Hwang
Paul M. Hwang
Doxorubicin is a widely used chemotherapeutic agent that causes dose-dependent cardiotoxicity in a subset of treated patients, but the genetic determinants of this susceptibility are poorly understood. Here, we report that a noncanonical tumor suppressor activity of p53 prevents cardiac dysfunction in a mouse model induced by doxorubicin administered in divided low doses as in the clinics. While relatively preserved in wild-type (p53+/+) state, mice deficient in p53 (p53−/−) developed left ventricular (LV) systolic dysfunction after doxorubicin treatment. This functional decline in p53−/− mice was associated with decreases in cardiac oxidative metabolism, mitochondrial mass, and mitochondrial genomic DNA (mtDNA) homeostasis. Notably, mice with homozygous knockin of the p53 R172H (p53172H/H) mutation, which like p53−/− state lacks the prototypical tumor suppressor activities of p53 such as apoptosis but retains its mitochondrial biogenesis capacity, showed preservation of LV function and mitochondria after doxorubicin treatment. In contrast to p53-null state, wild-type and mutant p53 displayed distinct mechanisms of transactivating mitochondrial transcription factor A (TFAM) and p53-inducible ribonucleotide reductase 2 (p53R2), which are involved in mtDNA transcription and maintenance. Importantly, supplementing mice with a precursor of NAD+ prevented the mtDNA depletion and cardiac dysfunction. These findings suggest that loss of mtDNA contributes to cardiomyopathy pathogenesis induced by doxorubicin administered on a schedule simulating that in the clinics. Given a similar mtDNA protection role of p53 in doxorubicin-treated human induced pluripotent stem cell (iPSC)-derived cardiomyocytes, the mitochondrial markers associated with cardiomyopathy development observed in blood and skeletal muscle cells may have prognostic utility. Significance Doxorubicin is a DNA-damaging agent that is highly effective against various types of cancers, but a subset of treated patients develop heart failure for unclear genetic reasons. In the current study using p53 mouse models, low-dose doxorubicin as administered in the clinics surprisingly revealed that the absence of p53 increases susceptibility to doxorubicin cardiotoxicity while a mutant of p53 that retains mitochondrial regulation is protective. Notably, promoting mitochondrial biogenesis with a simple vitamin supplement ameliorated the cardiotoxicity. Furthermore, mitochondrial blood markers observed in association with doxorubicin susceptibility could provide guidance for the safer use of this effective chemotherapy.